Fund Holdings — Fairmount Funds Management LLC

Total Portfolio Value:
$1.59B
Total Bought:
$483.90M
Total Sold:
$266.26M
Net Transaction:
+$217.63M
Notable People:
Tomas Kiselak, Peter Evan Harwin
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
Oruka Therapeutics, Inc.(ORKA)3,705,2623,705,2620$352.63M$308.61M19.35%-$44.02M
Korsana Biosciences Inc09,103,729+9,103,729$0$291.32M18.27%+$291.32M
Dianthus Therapeutics, Inc.(DNTH)2,537,1912,537,1910$247.33M$223.40M14.01%-$23.93M
Damora Therapeutics Inc08,713,000+8,713,000$0$185.41M11.63%+$185.41M
Cogent Biosciences, Inc.(COGT)5,503,4185,503,4180$212.98M$176.22M11.05%-$36.76M
Viridian Therapeutics, Inc.(VRDN)5,090,9285,090,9280$93.52M$104.82M6.57%+$11.30M
Enliven Therapeutics Inc1,855,6441,855,6440$94.17M$85.06M5.33%-$9.11M
Jade Biosciences Inc4,553,4944,553,4940$101.18M$63.98M4.01%-$37.20M
Zenas BioPharma, Inc.(ZBIO)2,359,0252,371,358+12,333$59.87M$63.96M4.01%+$4.08M
Crescent Biopharma, Inc.(CBIO)2,747,8663,601,316+853,450$49.46M$52.54M3.30%+$3.08M
Faeth Therapeutics, Inc.(FTH)722,020722,0200$18.05M$21.47M1.35%+$3.42M
Inhibikase Therapeutics, Inc.(IKT)8,625,0008,625,0000$17.51M$17.72M1.11%+$215.6K
Apogee Therapeutics Inc298,6470-298,647$39.64M$0—-$39.64M
Damora Therapeutics, Inc.(DMRA)8,713,0000-8,713,000$226.63M$0—-$226.63M
Page 1 of 1
Fairmount Funds Management LLC — 13F Holdings — Q3 2026 | TickerTrail